- ASH data reinforce survival benefits of front-line AYVAKIT (avapritinib) use in patients with advanced SM
- Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT
Reported Saturday, Blueprint Medicines Showcases AYVAKIT'S Survival Benefits And Disease-Modifying Effects In Advanced Systemic Mastocytosis At ASH 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.